NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
- Recruiting
- Jun 25, 2021
- 1 min read
Updated: May 24, 2022
REST
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal dexamethasone until disease progression. The primary objective of this study is the MRD negativity rate during and/or after first 18 cycles of study treatment.
Sponsor
Oslo University Hospital
Collaborators
St. Olavs Hospital
Helse Stavanger HF
Information provided by (Responsible Party)
Fredrik Hellem Schjesvold, Oslo University Hospital
Location
Norway
ClinicalTrials.gov Identifier: NCT04939844
Official Title: Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma
First Posted: June 25, 2021
Click here for details on ClinicalTrials.gov
Drug: Isatuximab, bortezomib, lenalidomide, dexamethasone
Location
Europe
Norway